Key Highlights
- Genezen acquires uniQure’s Lexington gene therapy operations.
- New strategic supply agreements for uniQure’s clinical portfolio and CSL’s HEMGENIX®.
- State-of-the-art viral vector facility in Lexington boosts Genezen’s capabilities.
- Lexington site becomes Genezen’s global AAV center of excellence.
- Additional growth equity from Ampersand Capital Partners supports the transaction.
Source: PR Newswire
Notable Quotes
- “I am thrilled to welcome the Lexington team and the addition of a state-of-the-art, licensed viral vector manufacturing facility to Genezen.” — Steve Favaloro, President and CEO at Genezen
- “We are pleased to have found a partner in Genezen to take the facility and team into its next phase of growth. We are excited to expand our relationship with Genezen and have them take on HEMGENIX® commercial supply from the Lexington manufacturing operation.” — Matt Kapusta, CEO at uniQure
SoHC's Take
Genezen’s acquisition of uniQure’s Lexington operations is a strategic move that significantly enhances Genezen’s manufacturing capabilities and scale in the gene therapy sector. This transaction not only strengthens Genezen’s infrastructure with a state-of-the-art viral vector facility but also positions the company as a leading player in the AAV manufacturing space. The inclusion of strategic supply agreements for uniQure’s clinical portfolio and CSL’s HEMGENIX® further underscores the importance of this acquisition in expanding Genezen’s market reach and service offerings. With additional funding from Ampersand Capital Partners, Genezen is well-positioned for continued growth and innovation in delivering advanced gene therapy solutions to its global clientele.
